OTCPK:REPR

Stock Analysis Report

Executive Summary

Repro Med Systems, Inc., doing business as RMS Medical Products, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Risks

  • Repro Med Systems has significant price volatility in the past 3 months.
  • Repro Med Systems is covered by less than 3 analysts.

Share Price & News

How has Repro Med Systems's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:REPR

0.8%

US Medical Equipment

1.1%

US Market


1 Year Return

179.7%

OTCPK:REPR

9.6%

US Medical Equipment

2.1%

US Market

REPR outperformed the Medical Equipment industry which returned 9.1% over the past year.

REPR outperformed the Market in United States of America which returned 2% over the past year.


Share holder returns

REPRIndustryMarket
7 Day0%0.8%1.1%
30 Day22.3%0.2%3.7%
90 Day86.0%2.7%2.3%
1 Year179.7%179.7%10.5%9.6%4.4%2.1%
3 Year966.7%966.7%69.5%64.3%47.0%37.4%
5 Year1198.7%1198.7%132.5%105.9%61.6%43.8%

Price Volatility Vs. Market

How volatile is Repro Med Systems's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Repro Med Systems undervalued based on future cash flows and its price relative to the stock market?

6319.12x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Repro Med Systems to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Repro Med Systems to establish if it is available at substantial discount.


Price Based on Earnings

Repro Med Systems is overvalued based on earnings compared to the US Medical Equipment industry average.

Repro Med Systems is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Repro Med Systems is poor value based on expected growth next year.


Price Based on Value of Assets

Repro Med Systems is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Repro Med Systems expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

203.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Repro Med Systems's revenue is expected to grow significantly at over 20% yearly.

Repro Med Systems's earnings are expected to grow significantly at over 20% yearly.

Repro Med Systems's revenue growth is expected to exceed the United States of America market average.

Repro Med Systems's earnings growth is expected to exceed the United States of America market average.

Repro Med Systems's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Repro Med Systems will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Repro Med Systems performed over the past 5 years?

5.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Repro Med Systems's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.

Repro Med Systems's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Repro Med Systems's 1-year earnings growth is negative, it can't be compared to the US Medical Equipment industry average.


Return on Equity

Repro Med Systems has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

It is difficult to establish if Repro Med Systems has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

Repro Med Systems has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Repro Med Systems's financial position?


Financial Position Analysis

Repro Med Systems is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Repro Med Systems's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Repro Med Systems has no debt.

Repro Med Systems currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Repro Med Systems has no debt, it does not need to be covered by operating cash flow.

Repro Med Systems has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Repro Med Systems has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Repro Med Systems's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Repro Med Systems's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Repro Med Systems's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Repro Med Systems has not reported any payouts.

Unable to verify if Repro Med Systems's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Repro Med Systems has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Repro Med Systems's salary, the management and board of directors tenure and is there insider trading?

0.6yrs

Average management tenure


CEO

Don Pettigrew (51yo)

0.6yrs

Tenure

US$160,208

Compensation

Mr. Donald B. Pettigrew, also known as Don, has been President and Chief Commercial Officer at Repro Med Systems, Inc. since September 4, 2018 and its Chief Executive Officer since February 1, 2019. Mr. Pe ...


CEO Compensation Analysis

Don's remuneration is lower than average for companies of similar size in United States of America.

Insufficient data for Don to compare compensation growth.


Management Age and Tenure

0.6yrs

Average Tenure

52yo

Average Age

The average tenure for the Repro Med Systems management team is less than 2 years, this suggests a new team.


Board Age and Tenure

0.8yrs

Average Tenure

63yo

Average Age

The average tenure for the Repro Med Systems board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$17,08317 Jun 19
Horton Capital Management, LLC
EntityCompany
Shares7,847
Max PriceUS$2.20
BuyUS$54,25018 Mar 19
James Beck
EntityIndividual
Role
Member of the Board of Directors
Director
Shares35,000
Max PriceUS$1.55
BuyUS$23,10005 Mar 19
Arthur Radin
EntityIndividual
Shares15,000
Max PriceUS$1.54
BuyUS$14,08027 Feb 19
Horton Capital Management, LLC
EntityCompany
Shares10,000
Max PriceUS$1.42
BuyUS$14,50026 Feb 19
Robert Allen
EntityIndividual
Role
Member of the Board of Directors
Director
Shares10,000
Max PriceUS$1.45
BuyUS$3,896,03629 Jan 19
Horton Capital Management, LLC
EntityCompany
Shares3,246,697
Max PriceUS$1.20
BuyUS$226,16919 Dec 18
Horton Capital Management, LLC
EntityCompany
Shares144,980
Max PriceUS$1.56
SellUS$9,168,96319 Dec 18
Andrew Sealfon
EntityIndividual
Shares8,128,513
Max PriceUS$1.13
SellUS$2,052,44919 Dec 18
Paul Baker
EntityIndividual
Shares1,819,547
Max PriceUS$1.13
BuyUS$13,40230 Nov 18
Horton Capital Management, LLC
EntityCompany
Shares9,573
Max PriceUS$1.40
BuyUS$20,36623 Nov 18
Horton Capital Management, LLC
EntityCompany
Shares13,869
Max PriceUS$1.48
BuyUS$51,77019 Nov 18
Horton Capital Management, LLC
EntityCompany
Shares33,000
Max PriceUS$1.59
BuyUS$93,73013 Nov 18
Horton Capital Management, LLC
EntityCompany
Shares57,000
Max PriceUS$1.69
BuyUS$124,22207 Nov 18
Horton Capital Management, LLC
EntityCompany
Shares72,787
Max PriceUS$1.75
BuyUS$70,41502 Nov 18
Horton Capital Management, LLC
EntityCompany
Shares45,129
Max PriceUS$1.62
BuyUS$45,31030 Oct 18
Horton Capital Management, LLC
EntityCompany
Shares30,652
Max PriceUS$1.48

Ownership Breakdown


Management Team

  • Dan Goldberger (60yo)

    Executive Chairman

    • Tenure: 1.2yrs
  • Karen Fisher (53yo)

    CFO, Treasurer & Corporate Secretary

    • Tenure: 4.7yrs
    • Compensation: US$273.00k
  • Don Pettigrew (51yo)

    CEO, President & Chief Commercial Officer

    • Tenure: 0.6yrs
    • Compensation: US$160.21k
  • Manny Marques (46yo)

    Chief Operating Officer

    • Tenure: 0.8yrs
  • Craig Ross

    Vice President of Sales & Marketing

    • Tenure: 0.2yrs

Board Members

  • Dan Goldberger (60yo)

    Executive Chairman

    • Tenure: 1.2yrs
  • R. Fletcher (73yo)

    Director

    • Tenure: 0.3yrs
  • David Anderson (66yo)

    Director

    • Tenure: 3.6yrs
    • Compensation: US$25.00k
  • Rob Allen (63yo)

    Director

    • Tenure: 0.8yrs
    • Compensation: US$1.83k
  • Joe Manko (53yo)

    Lead Director

    • Tenure: 1.2yrs
    • Compensation: US$25.00k
  • Jim Beck (71yo)

    Director

    • Tenure: 0.8yrs
    • Compensation: US$1.83k
  • Kathy Frommer (60yo)

    Director

    • Tenure: 0.4yrs

Company Information

Repro Med Systems, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Repro Med Systems, Inc.
  • Ticker: REPR
  • Exchange: OTCPK
  • Founded: 1980
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$159.552m
  • Shares outstanding: 39.89m
  • Website: https://www.rmsmedicalproducts.com

Number of Employees


Location

  • Repro Med Systems, Inc.
  • 24 Carpenter Road
  • Chester
  • New York
  • 10918
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
REPROTCPK (Pink Sheets LLC)YesCommon StockUSUSDMar 1987

Biography

Repro Med Systems, Inc., doing business as RMS Medical Products, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internatio ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 23:40
End of Day Share Price2019/09/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.